Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab combinations in advanced solid tumors
NCT02174172Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2014
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma and 1 more (5 arms), sponsored by Roche. Primary endpoints: Recommended Phase II Dose at 21 days and Percentage of Participants with Adverse Events at 4.5 years. Started Aug 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02174172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174172.